[{"id":"40d267f0-e1ed-4b91-88c1-24b890045dbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05901935","created_at":"2023-06-13T17:08:09.374Z","updated_at":"2024-07-02T16:35:45.856Z","phase":"Phase 3","brief_title":"DP303c in Patients With HER2-positive Advanced Breast Cancer","source_id_and_acronym":"NCT05901935","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • vinorelbine tartrate • trastuzumab envedotin (DP303c)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-06-13"},{"id":"b414fa64-f178-4986-a5ff-2c88f3a21278","acronym":"","url":"https://clinicaltrials.gov/study/NCT04828616","created_at":"2021-04-02T11:53:35.097Z","updated_at":"2024-07-02T16:36:32.421Z","phase":"Phase 2","brief_title":"Study of DP303c Injection in Patients With Advanced Ovarian Cancer","source_id_and_acronym":"NCT04828616","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab envedotin (DP303c)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2021-04-02"},{"id":"6979cef1-b4b7-443c-8e4f-a64b76aeed5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826107","created_at":"2021-04-01T16:52:31.994Z","updated_at":"2024-07-02T16:36:32.510Z","phase":"Phase 2","brief_title":"Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer","source_id_and_acronym":"NCT04826107","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab envedotin (DP303c)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-04-01"},{"id":"72936583-40f5-4834-b27a-a4031ff19ead","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146610","created_at":"2021-01-18T20:14:16.592Z","updated_at":"2024-07-02T16:36:54.092Z","phase":"Phase 1","brief_title":"Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors","source_id_and_acronym":"NCT04146610","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab envedotin (DP303c)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2019-10-31"}]